Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Jan 25, 2025. (Total: 235671Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 17 (of 17 Records)

Query Trace: Atrial Fibrillation and CYP3A5[original query]
Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Pharmacogenetics and genomics 2017 Jul .
Ueshima Satoshi, Hira Daiki, Fujii Ryo, Kimura Yuuma, Tomitsuka Chiho, Yamane Takuya, Tabuchi Yohei, Ozawa Tomoya, Itoh Hideki, Horie Minoru, Terada Tomohiro, Katsura Toshi
Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke.
Pharmacogenomics and personalized medicine 2018 4 11 43-49.
Kryukov Alexander Valerevich, Sychev Dmitry Alekseevich, Andreev Denis Anatolevich, Ryzhikova Kristina Anatolievna, Grishina Elena Anatolievna, Ryabova Anastasia Vladislavovna, Loskutnikov Mark Alekseevich, Smirnov Valeriy Valerevich, Konova Olga Dmitrievna, Matsneva Irina Andreevna, Bochkov Pavel Olegovi
Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
British journal of clinical pharmacology 2018 Feb .
Ueshima Satoshi, Hira Daiki, Kimura Yuuma, Fujii Ryo, Tomitsuka Chiho, Yamane Takuya, Tabuchi Yohei, Ozawa Tomoya, Itoh Hideki, Ohno Seiko, Horie Minoru, Terada Tomohiro, Katsura Toshi
Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care.
Journal of thrombosis and thrombolysis 2019 Sep .
Gulilat Markus, Keller Denise, Linton Bradley, Pananos A Demetri, Lizotte Daniel, Dresser George K, Alfonsi Jeffrey, Tirona Rommel G, Kim Richard B, Schwarz Ute
Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Basic & clinical pharmacology & toxicology 2020 Sep .
Nakagawa Junichi, Kinjo Takahiko, Iizuka Mei, Ueno Kayo, Tomita Hirofumi, Niioka Takeno
CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.
Pharmacogenomics and personalized medicine 2020 3 13 29-37.
Sychev D A, Baturina O A, Mirzaev K B, Rytkin E, Ivashchenko D V, Andreev D A, Ryzhikova K A, Grishina E A, Bochkov P O, Shevchenko R
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K? inhibitor therapy.
Blood 2020 12 137 (20): 2817-2826.
Mato Anthony R, Ghosh Nilanjan, Schuster Stephen J, Lamanna Nicole, Pagel John M, Flinn Ian W, Barrientos Jacqueline C, Rai Kanti R, Reeves James A, Cheson Bruce D, Barr Paul M, Kambhampati Suman, Lansigan Frederick, Pu Jeffrey J, Skarbnik Alan P, Roeker Lindsey, Fonseca Gustavo A, Sitlinger Andrea, Hamadeh Issam S, Dorsey Colleen, LaRatta Nicole, Weissbrot Hanna, Luning Prak Eline T, Tsao Patricia, Paskalis Dana, Sportelli Peter, Miskin Hari P, Weiss Michael S, Svoboda Jakub, Brander Danielle
Associations among plasma concentrations of edoxaban and M-4, prothrombin time, and the SLCO1B1*15 haplotype in patients with non-valvular atrial fibrillation.
Therapeutic drug monitoring 2022 Sep .
Nakagawa Junichi, Kinjo Takahiko, Aiuchi Naoya, Ueno Kayo, Tomita Hirofumi, Niioka Takeno
Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients.
Frontiers in pharmacology 2022 12 13 1007113.
Campos-Staffico Alessandra M, Dorsch Michael P, Barnes Geoffrey D, Zhu Hao-Jie, Limdi Nita A, Luzum Jasmine
Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation.
European journal of clinical pharmacology 2022 11 79 (1): 127-135.
Nakagawa Junichi, Kinjo Takahiko, Aiuchi Naoya, Ueno Kayo, Tomita Hirofumi, Niioka Takeno
Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events.
Frontiers in genetics 2022 10 13 982955.
Attelind Sofia, Hallberg Pär, Wadelius Mia, Hamberg Anna-Karin, Siegbahn Agneta, Granger Christopher B, Lopes Renato D, Alexander John H, Wallentin Lars, Eriksson Nicl
Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.
Pharmacogenetics and genomics 2022 Oct .
Sychev Dmitry Alekseevitch, Sokolov Aleksey Vladimirovich, Reshetko Olga Vilorovna, Fisenko Vladimir Petrovich, Sychev Igor Nikolaevich, Grishina Elena Anatolievna, Bochkov Pavel Olegovich, Shevchenko Roman Vladimirovich, Abdullaev Sherzod Pardaboevich, Denisenko Natalia Pavlovna, Ivashchenko Dmitry Vladimirovich, Sozaeva Zhannet Alimovna, Kachanova Anastasia Alekseev
Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation.
Cardiovascular drugs and therapy 2023 8 .
Xiaoye Li, Zhichun Gu, Zi Wang, Qing Xu, Chunlai Ma, Qianzhou
ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban.
Drug design, development and therapy 2023 8 17 2513-2522.
Hamin Kim, Tae-Jin Song, Jeong Yee, Dong-Hyeok Kim, Junbeom Park, Hye Sun Gw
The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation.
Human genomics 2023 7 17 (1): 59.
Tingting Wu, Shuyi Wu, Li Li, Jing Xiang, Na Wang, Wenjun Chen, Jinhua Zha
The impact of ABCB1, CYP3A4 and CYP3A5 gene polymorphisms on apixaban trough concentration and bleeding risk in patients with atrial fibrillation.
Drug metabolism and personalized therapy 2024 6 .
Alena I Skripka, Pavel M Krupenin, Olga N Kozhanova, Anna A Kudryavtseva, Ludmila V Fedina, Kristina A Akmalova, Pavel O Bochkov, Anastasiya A Sokolova, Dmitriy A Napalkov, Dmitriy A Sych
Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up.
Medicina (Kaunas, Lithuania) 2024 10 60 (10): .
Nur Ul Ain, Niaz Ali, Abid Ullah, Shakir Ullah, Shujaat Ahm
TOP